Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks Chelsea for your response. I just wanted to know if there are actually any trials in progress at the moment.
Or is it farmed out to someone in the US. I saw an application for a US IND that didnt make the standard. So i presume that would be the near term boost.
Its looking cheap if trials are happening but im sick of investing in pharmas that just pay the wages for the staff and do nothing.
And the rest. It will either continue or go back to 1.50. No news again
http://allamed.ru/administaciya-po-kontrolyu-za-prodovolestvennimi-i-farmacevtic.html
Para - is that Russian one even running? I think the whole thing is a joke now. Wonder will we ever see close to what we paid. If the results are good it could be 100 dollars but knowing our luck it will come in and boom
Seems they trying to keep somethings secret or they just too useless to get filing on time
On February 27, 2017, Pharmsynthez acquired 100% of SynBio. As a result, SynBio’s ownership stake is reflected as part of Pharmsynthez’ share ownership. Pharmsynthez, directly and indirectly through SynBio, has a share ownership in the Company of approximately 61.5% of the total issued common stock as of December 31, 2017.
SynBio applied for and received regulatory approval to commence ErepoXen Phase II(b)/III human clinical trials in Russia and is currently recruiting patients. SynBio has indicated that it intends to commence the commercialization and marketing stages of ErepoXen in the Russian and CIS markets subject to approval in such markets.
Still small shareholders Holders of Record As of March 9, 2018, there were 424 holders of record of our common stock.
Highlights - thought this was dead SynBio applied for and received regulatory approval to commence ErepoXen Phase II(b)/III human clinical trials in Russia and is currently recruiting patients. SynBio has indicated that it intends to commence the commercialization and marketing stages of ErepoXen in the Russian and CIS markets subject to approval in such markets.
4:55 PolyXen: A Polysialylation Technology for Enhancing Therapeutic Proteins and Their Clinical Applications Curtis Lockshin, PhD, Chief Scientific Officer, Xenetic Biosciences, Inc. PolyXen™ is a proprietary platform for conjugating polysialic acid (PSA) to protein or peptide therapeutics, which can improve their pharmacological properties. Preclinical and human clinical data has been generated with a number of compounds, including recombinant Factor VIII, rhEPO, and oxyntomodulin. Therapeutic proteins polysialylated with the PolyXen platform have displayed extended circulating half-life, improved thermodynamic stability and protease resistance, while retaining pharmacological activity. We have seen no evidence to date of PSA- induced immunogenicity, an issue commonly associated with PEG.
I was wrong
https://d1io3yog0oux5.cloudfront.net/_328648ecd9e6b2116e7b1186279bb754/xeneticbio/db/213/1176/pdf/Xenetic_Presentation_February+2018.pdf New IR people too
9,182 from corp presentation in DEC Insiders own 8,697 of all potential shares thats 94.7% so much for bloody liquidity....
My theory is there is no new collaboration with Baxter - it was a payoff. Made to look like this instead of saying your product is useless. Otherwise where is it? So down to one now...... Where is the other products gone.......... All smoke and mirrors..... One positive is they been giving that XBIO-101 to millions safely for years in Russia and seem to have results from the presentation below in Estonia
This year rodders..... this year.
thats two giveaways on the last working day before christmas. This time its the biggest ever
Is this the goose that laid the golden egg. Nothing on it for over a year https://multiplesclerosisnewstoday.com/2016/06/30/new-MS-vaccine-soon-to-enter-phase-3-testing/